Javascript must be enabled to continue!
Reflex Xpert MTB/XDR Testing of Residual Rifampicin-Resistant Specimens: A Clinical Laboratory-Based Diagnostic Accuracy and Feasibility Study in South Africa
View through CrossRef
Abstract
Background
The World Health Organization–approved Xpert MTB/XDR test detects Mycobacterium tuberculosis and resistance to isoniazid, fluoroquinolones, ethionamide, and injectable drugs directly in specimens. This pragmatic, laboratory-based study assessed the diagnostic accuracy and feasibility of a reflex testing approach, where Xpert MTB/XDR was performed on residual specimens previously processed for Xpert MTB/RIF Ultra.
Methods
Routine respiratory specimens, processed for Xpert MTB/RIF Ultra, were stored in sample reagent buffer at 2°C–8°C. If rifampicin resistant, the residual specimen was assessed for adequate volume (≥2 mL) and tested with Xpert MTB/XDR, with storage time recorded. A second specimen was used for routine and reference standard testing (culture and sequencing).
Results
Specimens (99% sputum) from 763 participants submitted to 2 large routine laboratories were included. Xpert MTB/XDR yielded valid resistance detection results in 639 (84%), compared with 507 (66%) for routine testing (difference [95% CI], 18% [13%–22%]). The median turnaround time for results was 23 hours for Xpert MTB/XDR and 15 days for routine testing. While 748 specimens (98%) were ≥2 mL, only 102 (13%) were stored for ≤4 hours. By the reference standard, 284 of 394 (72%) were isoniazid resistant, and 57 of 380 (15%) were fluroquinolone resistant. The sensitivities of Xpert MTB/XDR were 94% (95% CI, 91%–97%) for isoniazid and 91% (81%–97%) for fluoroquinolone resistance detection. The specificities were 98% (94%–100%) and 100% (98%–100%), respectively.
Conclusions
Xpert MTB/XDR performed favorably compared with the reference, and the reflex testing approach increased results availability over routine testing, while dramatically decreasing turnaround time from weeks to hours. Laboratory workflow precluded testing within the manufacturer-recommended 4-hour storage time, but longer storage did not appear detrimental.
Oxford University Press (OUP)
C M Centner
R Munir
E Tagliani
F Rieß
P Brown
C Hayes
T Dolby
W Zemanay
D M Cirillo
A David
S G Schumacher
C M Denkinger
M Ruhwald
V N Leukes
M P Nicol
I Van der Walt
G Kisten
M Gumede
A Mace
A Brink
W Stevens
L Scott
A Penn-Nicholson
H Cox
Vinzeigh Leukes
Adam Penn-Nicholson
Morten Ruhwald
Berra Erkosar
Samuel G Schumacher
Sunita Singh
Bernard Kivuma
Muhuminu Nuru
Judith Mlenge
Neema Shija
Deogratias Bulime
Dorcas Mnzava
Petro Sabuni
Hosiana Temba
Jamali Siru
Jerry Hella
Jonathan Msafiri
Maja Weisser
Mohamed Mbaruku
Mohamed Sasamalo
Alice Leonard
Ambilikile Malango
Annastazia Alexander
Faith Komakoma
Gloria Msigala
Kasmir Johaness
Grace Mhalu
Mwajabu Hamis
Priscilla Mlay
Robert Ndege
Sera Barasa
Swalehe Masoud
Theonestina Byakuzana
Anange Lwilla
Benedict Kayombo
Chacha Mangu
Christina Manyama
Theodora Mbunda
Elimina Siyame
Issa Sabi
Last Mwaipopo
Nyanda Elias Ntinginya
Raphael Edom
Willyhelmina Olomi
Delio Elisio
Dinis Nguenha
Edson Mambuque
Joaquim Cossa
Marta Cossa
Neide Gomes
Patricia Manjate
Shilzia Munguambe
Sozinho Acacio
Belen Saavedra
Helio Chiconela
Katia Ribeiro
António Machiana
Bindiya Meggi
Candido Azize Junior
Carla Madeira
Celso Khosa
Claudio Bila
Denise Floripes
Diosdélio Malamule
Sofia Viegas
Belén Saavedra
Carole Amroune
Joanna Ehrlich
Laura de la Torre Pérez
Sergi Sanz
Albero Garcia-Basteiro
Friedrich Riess
Sarah Mutuku
Tejaswi Appalarowthu
Leyla Larson
Katharina Kranzer
Michael Hoelscher
Norbert Heinrich
Maria del Mar Castro Noriega
Claudia M Denkinger
Saima Arif
Daniela Maria Cirillo
Elisa Tagliani
Federico Di Marco
Virginia Batignani
Akash Malhotra
David Dowdy
Claudia Schacht
Julia Buech
Caroline Stöhr
Marguerite Massinga Loembé
Pascale Ondoa
Nqobile Ndlovu
Fumbani Brown
Yonas Ghebrekristos
Cindy Hayes
Ilse Van der Walt
Shareef Abrahams
Puleng Marokane
Mbuti Radebe
Neil Martinson
Anura David
Lesley Scott
Lucky Ngwenya
Pedro Da Silva
Reyhana Solomon
Wendy Stevens
Charles Abongomera
Klaus Reither
Leon Stieger
Adrian Brink
Chad M Centner
Helen Cox
Judi van Heerden
Mark P Nicol
Nchimunya Hapeela
Parveen Brown
Reyhana Solomon
Widaad Zemanay
Tania Dolby
Title: Reflex Xpert MTB/XDR Testing of Residual Rifampicin-Resistant Specimens: A Clinical Laboratory-Based Diagnostic Accuracy and Feasibility Study in South Africa
Description:
Abstract
Background
The World Health Organization–approved Xpert MTB/XDR test detects Mycobacterium tuberculosis and resistance to isoniazid, fluoroquinolones, ethionamide, and injectable drugs directly in specimens.
This pragmatic, laboratory-based study assessed the diagnostic accuracy and feasibility of a reflex testing approach, where Xpert MTB/XDR was performed on residual specimens previously processed for Xpert MTB/RIF Ultra.
Methods
Routine respiratory specimens, processed for Xpert MTB/RIF Ultra, were stored in sample reagent buffer at 2°C–8°C.
If rifampicin resistant, the residual specimen was assessed for adequate volume (≥2 mL) and tested with Xpert MTB/XDR, with storage time recorded.
A second specimen was used for routine and reference standard testing (culture and sequencing).
Results
Specimens (99% sputum) from 763 participants submitted to 2 large routine laboratories were included.
Xpert MTB/XDR yielded valid resistance detection results in 639 (84%), compared with 507 (66%) for routine testing (difference [95% CI], 18% [13%–22%]).
The median turnaround time for results was 23 hours for Xpert MTB/XDR and 15 days for routine testing.
While 748 specimens (98%) were ≥2 mL, only 102 (13%) were stored for ≤4 hours.
By the reference standard, 284 of 394 (72%) were isoniazid resistant, and 57 of 380 (15%) were fluroquinolone resistant.
The sensitivities of Xpert MTB/XDR were 94% (95% CI, 91%–97%) for isoniazid and 91% (81%–97%) for fluoroquinolone resistance detection.
The specificities were 98% (94%–100%) and 100% (98%–100%), respectively.
Conclusions
Xpert MTB/XDR performed favorably compared with the reference, and the reflex testing approach increased results availability over routine testing, while dramatically decreasing turnaround time from weeks to hours.
Laboratory workflow precluded testing within the manufacturer-recommended 4-hour storage time, but longer storage did not appear detrimental.
Related Results
The Value of Lateral Flow Urine Lipoarabinomannan Assay and Empirical Treatment in the Xpert MTB/RIF Ultra Era: a Prospective Cohort Study
The Value of Lateral Flow Urine Lipoarabinomannan Assay and Empirical Treatment in the Xpert MTB/RIF Ultra Era: a Prospective Cohort Study
Abstract
Introduction: The value of Lateral Flow urine Lipoarabinomannan (LF-LAM) assay and the role of empiric tuberculosis (TB) treatment in the era of the highly sensiti...
The value of lateral flow urine lipoarabinomannan assay and empirical treatment in Xpert MTB/RIF ultra negative patients with presumptive TB: a prospective cohort study
The value of lateral flow urine lipoarabinomannan assay and empirical treatment in Xpert MTB/RIF ultra negative patients with presumptive TB: a prospective cohort study
AbstractThe value of Lateral Flow urine Lipoarabinomannan (LF-LAM) assay and the role of empiric tuberculosis (TB) treatment in the era of the highly sensitive Xpert MTB/RIF Ultra ...
Diagnostic accuracy of swab-based molecular tests for tuberculosis using novel near point-of-care platforms: A multi-country evaluation
Diagnostic accuracy of swab-based molecular tests for tuberculosis using novel near point-of-care platforms: A multi-country evaluation
SummaryBackgroundSwab-based molecular platforms that enable testing of both sputum (via swabs swirled in sputum) and tongue swabs are emerging as a promising option for more access...
Does Xpert MTB/RIF Assay Give Rifampicin Resistance Results Without Identified Mutation? Review of Cases from Addis Ababa, Ethiopia.
Does Xpert MTB/RIF Assay Give Rifampicin Resistance Results Without Identified Mutation? Review of Cases from Addis Ababa, Ethiopia.
Abstract
Background: Xpert® MTB/RIF assay is currently used in Ethiopia for the rapid diagnosis of Mycobacterium tuberculosis (MTB) and mutations that confer Rifampicin res...
Does Xpert MTB/RIF Assay Give Rifampicin Resistance Results Without Identified Mutation? Review of Cases from Addis Ababa, Ethiopia.
Does Xpert MTB/RIF Assay Give Rifampicin Resistance Results Without Identified Mutation? Review of Cases from Addis Ababa, Ethiopia.
Abstract
Background: Xpert MTB/RIF Assay is currently used in Ethiopia for the rapid diagnosis of Mycobacterium tuberculosis (MTB) and mutations that confer Rifampicin resi...
Quality assurance practices in tuberculosis diagnostic health facilities in Ethiopia
Quality assurance practices in tuberculosis diagnostic health facilities in Ethiopia
Introduction
The quality of tuberculosis laboratory services in health facilities is a mandatory component of detecting active pulmonary TB cases and treatment follow-up. However, ...
Clinical spectrum of admitted patients undergoing Xpert MTB/RIF® testing for tuberculosis evaluation at a tertiary care hospital
Clinical spectrum of admitted patients undergoing Xpert MTB/RIF® testing for tuberculosis evaluation at a tertiary care hospital
Abstract
Background:
The introduction of Xpert MTB/RIF® has revolutionised the diagnosis of tuberculosis (TB) by reducing time to the identificat...
Comparison of Interpretation between Pyrosequencing and Xpert MTB/RIF Assay in Multidrug-Resistant Tuberculosis
Comparison of Interpretation between Pyrosequencing and Xpert MTB/RIF Assay in Multidrug-Resistant Tuberculosis
Indonesia is one of the countries with the highest multidrug-resistant tuberculosis cases in the world. Rapid molecular test using the Xpert MTB/RIF assay is one of the detection m...


